<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799992</url>
  </required_header>
  <id_info>
    <org_study_id>CSC0001</org_study_id>
    <nct_id>NCT02799992</nct_id>
  </id_info>
  <brief_title>Pseudo-PDT in Central Serous Chorioretinopathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università degli Studi di Brescia</source>
  <brief_summary>
    <textblock>
      Acute central serous chorioretinopathy (CSC) is a common disorder in middle-aged patients,
      characterized by serous retinal detachment in the macular region. We evaluated half-dose
      verteporfin photodynamic therapy (hd-PDT) versus 689 nm laser treatment in chronic CSC.

      Twenty-two eyes of 22 patients with symptomatic chronic CSC were randomized in a 1:1 ratio to
      receive hd-PDT (group 1) or 689-LT delivering 95 J/cm2 by application of an intensity of 805
      mW/cm2 over 118 seconds. Best-corrected visual acuity (BCVA) and spectral-domain optical
      coherence tomography findings were compared between groups.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best-corrected Visual Acuity (LogMAR)</measure>
    <time_frame>6 months</time_frame>
    <description>Measured with ETDRS chart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Central Retinal Thickness (micron)</measure>
    <time_frame>6 months</time_frame>
    <description>Measured with OCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subfoveal Choroidal Thickness (micron)</measure>
    <time_frame>6 months</time_frame>
    <description>Measured with OCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ellipsoid Zone Recovery (integrity of IS/OS line)</measure>
    <time_frame>6 months</time_frame>
    <description>As visible with OCT scans</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Chronic Central Serous Chorioretinopathy</condition>
  <arm_group>
    <arm_group_label>Half Dose Photodynamic Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half Dose Photodynamic Therapy The safety enhanced PDT protocol for CSC was performed using half the normal dose of verteporfin (Visudyne, Novartis Pharma, Switzerland), which is 3 mg/m2 verteporfin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>689 nm Laser Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 689 nm laser treatment delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds was performed. No verteporfin or other drugs were administered to the patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>689 nm Laser Treatment of the Macula</intervention_name>
    <arm_group_label>689 nm Laser Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Half Dose Photodynamic Therapy</intervention_name>
    <arm_group_label>Half Dose Photodynamic Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥18 years;

          -  patients with best-corrected visual acuity (BCVA) of 20/200 or better;

          -  presence of subretinal fluid (SRF) and/or serous pigment epithelial detachment
             involving the fovea on optical coherence tomography (OCT);

          -  presence of active angiographic leakage in fluorescein angiography caused by CSC and
             no other diseases, and abnormal dilated choroidal vasculature and other features in
             indocyanine green angiography (ICGA) consistent with the diagnosis of CSC.

        Exclusion Criteria:

          -  any previous treatment for CSC;

          -  evidence of choroidal neovascularization or other maculopathy on fundus examination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Russo, MD, PhD</last_name>
    <phone>+390303995308</phone>
    <email>dott.andrea.russo@gmail.com</email>
  </overall_contact>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi di Brescia</investigator_affiliation>
    <investigator_full_name>Andrea Russo</investigator_full_name>
    <investigator_title>MD, PhD Candidate</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

